Feb 1, 2025, 07:52
Shaalan Beg: Poll Insights on BREAKWATER Trial Results
Shaalan Beg, Senior Advisor for Clinical Research at the National Cancer Institute, posted the following on X:
“Interesting insights from our poll on the BREAKWATER trial results. Nearly a quarter of respondents will wait for final OS data before offering Enco+Cetux_FOLFOX routinely for newly diagnosed BRAFV600E mutated CRC.”
BRAF mutation
BRAFV600E
BREAKWATER trial
cancer
Cancer Management
Clinical Decision Making
clinical trial outcomes
colorectal cancer
CRC treatment
Enco+Cetux_FOLFOX
FOLFOX
OncoDaily
Oncology
oncology research
patient care
Phase 3 Trial
poll results
Shaalan Beg
survival data
targeted therapy
Treatment Strategies
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 1, 2025, 07:52
Feb 1, 2025, 07:32
Feb 1, 2025, 07:30
Feb 1, 2025, 07:29
Feb 1, 2025, 07:26
Feb 1, 2025, 07:20
Feb 1, 2025, 07:19